FRAXA Research Foundation

Funding Profiles

Access available for Technion staff. Please sign in to see the Agency profiles (upper left corner)

FRAXA's mission is to accelerate progress toward effective treatments and ultimately a cure for Fragile X, by directly funding the most promising research.

FRAXA also supports families affected by Fragile X and raises awareness of this important but virtually unknown disease.

FRAXA was founded in 1994 by three parents of children with Fragile X, Katie Clapp, Michael Tranfaglia MD, and Kathy May, to support scientific research aimed at finding a treatment and a cure for Fragile X. Fragile X research is drastically underfunded, considering its high prevalence, prospects for a cure, and the promise that this research holds for advancing understanding of other disorders like autism, Alzheimer's disease, and X-linked mental retardation.

Contact information:

Michael Tranfaglia, MD
Medical Director
FRAXA Research Foundation
45 Pleasant St. Second Floor
Newburyport, MA 01950

For further information contact Michael Tranfaglia
Phone (978) 462-1866
Fax: (978) 463-9985

The fund is not a competitive fund
web site: http://www.fraxa.org/